Johnson & Johnson's IMAAVY Data Reinforces Narrative in Rare Disease Market

Johnson & Johnson (JNJ) has reported new two-year IMAAVY data in generalized myasthenia gravis (gMG), including adolescent outcomes. The update covered sustained disease control, functional improvement measures, and long-term safety results in adolescent gMG patients.

The data also included information on corticosteroid use and therapy transition patterns in adult gMG from healthcare provider surveys.

This kind of rare disease work at Johnson & Johnson is part of its broader push in complex immune and neuromuscular disorders, where treatment options remain limited.

The IMAAVY data reinforce the existing narrative that next-generation immunology drugs need to take over from older blockbusters facing loss of exclusivity.